Sector News

ConvaTec Appoints Paul Moraviec CEO Effective April 30, 2015

May 1, 2015
Life sciences
/PRNewswire/ – ConvaTec, a privately-held medical products and technologies company, today announced that Paul Moraviec has been appointed Chief Executive Officer of the company.
 
Mr. Moraviec was appointed Interim CEO of ConvaTec in December 2014. “We are pleased to confirm Paul’s appointment as the CEO of ConvaTec,” said Magnus Lundberg, the Chairman of ConvaTec’s Board of Directors. “Over his six years with ConvaTec, Paul has built a successful business in Europe, and the company has performed well during his tenure as Interim CEO. We’re confident that, under his leadership, the company is well positioned for the future.” 
 
“I look forward to working with the Board as the CEO of ConvaTec,” said Paul Moraviec. “I’m very excited about the future for our business and leading the company’s 9,000 employees in serving the patients, doctors and nurses who rely on us to help improve lives around the world.”
 
Mr. Moraviec joined ConvaTec in 2009 as President, Europe, Middle East and Africa, which is the company’s largest geographic region. Mr. Moraviec has a track record of driving growth in major global healthcare companies across a number of medical device specialties including diabetes, neurosurgery, general surgery and orthopedics. 
 
Mr. Moraviec has held international leadership roles with Johnson & Johnson, Abbott Laboratories and Bausch and Lomb, as well as CEO roles with two early-stage venture capital funded companies.
 
Source: ConvaTec

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).